BRIDGEWATER, N.J.– Cosette Pharmaceuticals, Inc (“Cosette”) began shipping Griseofulvin Oral Suspension, 125 mg/5 mL (0713-0850-04) into all channels in the United States.
This launch will provide much needed access to patients and providers for a product which has been supply constrained. The finished product will be manufactured in the United States.
Apurva Saraf, President and CEO of Cosette Pharma, stated, “This approval and immediate launch demonstrates our ability to continue transforming Cosette, by launching important products through our drug development, supply chain management and manufacturing expertise. This is in addition to a long list of new product launches this year, and is a testament to how we are Innovating Every Day.”
According to IQVIA™, U.S. market annual sales for the 12 months ended October 2022 for Griseofulvin Oral Suspension, 125 mg/5 mL is estimated to be approximately $12 million.
